Clinical Oral Investigations

, Volume 15, Issue 2, pp 127–139

Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD

  • Johannes K.-H. Meier
  • Daniel Wolff
  • Steve Pavletic
  • Hildegard Greinix
  • Martin Gosau
  • Hartmut Bertz
  • Stefanie J. Lee
  • Ánita Lawitschka
  • Sharon Elad


Chronic graft-versus-host disease (cGVHD) is a multi-organ disease that occurs post-hematopoietic stem cell transplantation, with the mouth being one of the most frequently affected organs. In 2009, the German–Austrian–Swiss working party on bone marrow and blood stem cell transplantation held a consensus conference to define clinical management of cGVHD. The consensus conference aimed to summarize the literature on diagnosis and topical treatment options for oral cGVHD and to provide recommendations for clinical practice, including routine dental and oral care as well as monitoring for secondary malignancies and bisphophonate-induced osteonecrosis of the jaw.


Oral cGVHD Topical Treatment Diagnosis 


  1. 1.
    Couriel D, Carpenter PA, Cutler C et al (2006) Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12(4):375–396PubMedCrossRefGoogle Scholar
  2. 2.
    Baird K, Pavletic SZ (2006) Chronic graft versus host disease. Curr Opin Hematol 13:426–435PubMedCrossRefGoogle Scholar
  3. 3.
    Schubert MM, Correa ME (2008) Oral graft-versus-host disease. Dent Clin North Am 52(1):79–109PubMedCrossRefGoogle Scholar
  4. 4.
    Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956PubMedCrossRefGoogle Scholar
  5. 5.
    Sullivan KM (2004) Graft vs. host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds) Thomas’ hematopoietic cell transplantation, 3rd edn. Blackwell, Malden, pp 635–664Google Scholar
  6. 6.
    Ferrara JL, Reddy P (2006) Pathophysiology of graft-versus host disease. Semin Hematol 43:3–10PubMedCrossRefGoogle Scholar
  7. 7.
    Martin RW 3rd, Farmer ER, Altomonte VL et al (1995) Lichenoid graft-vs-host disease in an autologous bone marrow transplant recipient. Arch Dermatol 131:333–335PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674):1550–1561PubMedCrossRefGoogle Scholar
  9. 9.
    Imanguli MM, Swaim WD, League SC et al (2009) Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 113(15):3620–3630PubMedCrossRefGoogle Scholar
  10. 10.
    Flowers ME, Parker PM, Johnston LJ et al (2002) Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100(2):415–419PubMedCrossRefGoogle Scholar
  11. 11.
    Woo SB, Lee SJ, Schubert MM (1997) Graft-vs.-host disease. Crit Rev Oral Biol Med 8:201–216PubMedCrossRefGoogle Scholar
  12. 12.
    Schubert MM, Sullivan KM, Morton TH et al (1984) Oral manifestations of chronic graft-versus-host disease. Arch Intern Med 144:1591–1595PubMedCrossRefGoogle Scholar
  13. 13.
    Schubert MM, Sullivan KM (1990) Recognition, incidence, and management of oral graft-versus host disease. NCI Monogr 9:135–143PubMedGoogle Scholar
  14. 14.
    Fox PC, Van der Ven P, Sonies BC, Weiffenbach JM, Baum BJ (1985) Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc 110:519–525PubMedGoogle Scholar
  15. 15.
    Porter SR, Scully C, Hegarty AM (2004) An update on the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:28PubMedCrossRefGoogle Scholar
  16. 16.
    da Fonseca MA, Murdoch-Kinch CA (2007) Severe gingival recession and early loss of teeth in a child with chronic graft versus host disease: a case report. Spec Care Dentist 27(2):59–63PubMedCrossRefGoogle Scholar
  17. 17.
    Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB (1977) Scleroderma, Sjögren’s-like syndrome, and chronic graft-versus-host disease. Ann Intern Med 87:707–709PubMedGoogle Scholar
  18. 18.
    Curtis RE, Rowlings PA, Deeg HJ et al (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336(13):897–904PubMedCrossRefGoogle Scholar
  19. 19.
    Demarosi F, Lodi G, Carrassi A et al (2005) Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 41(9):865–877PubMedCrossRefGoogle Scholar
  20. 20.
    Otsubo H, Yokoe H, Miya T et al (1997) Gingival squamous cell carcinoma in a patient with chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84(2):171–174PubMedCrossRefGoogle Scholar
  21. 21.
    Treister NS, Woo SB, O’Holleran EW, Lehmann LE, Parsons SK, Guinan EC (2005) Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11(9):721–731PubMedCrossRefGoogle Scholar
  22. 22.
    Pavletic SZ, Martin P, Lee SJ et al (2006) Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 12(3):252–266PubMedCrossRefGoogle Scholar
  23. 23.
    Elad S, Zeevi I, Or R et al (2010) Validation of the National Institute of Health (NIH) Scale for oral chronic graft versus host disease (cGVHD). Biol Blood Marrow Transplant 16(1):62–69, Epub 2009 Sep 3PubMedCrossRefGoogle Scholar
  24. 24.
    Treister N, Stevenson K, Kim H (2009) Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant 16(1):108–114, Epub 2009 Sep 17PubMedCrossRefGoogle Scholar
  25. 25.
    Imanguli MM, Pavletic SZ, Guadagnini JP et al (2006) Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101(2):175–183PubMedCrossRefGoogle Scholar
  26. 26.
    Wolff D, Gerbitz A, Ayuk F et al. (2010) Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2010.06.015
  27. 27.
    Elad S, Or R, Garfunkel AA, Shapira MY (2003) Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95(3):308–311PubMedCrossRefGoogle Scholar
  28. 28.
    Sari I, Altuntas F, Kocyigit I et al (2007) The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 82(5):349–356PubMedCrossRefGoogle Scholar
  29. 29.
    Dilger K, Halter J, Bertz H et al (2009) Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 15(3):336–343PubMedCrossRefGoogle Scholar
  30. 30.
    Wolff D, Anders V, Corio R et al (2004) Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed 20:184–9059PubMedCrossRefGoogle Scholar
  31. 31.
    National Cancer Institute (2009) Graft-versus-host disease.
  32. 32.
    França CM, Domingues-Martins M, Volpe A, Pallotta Filho RS, SoaresdeAraújo N (2001) Severe oral manifestations of chronic graft-vs.-host disease. J Am Dent Assoc 132(8):1124–1127PubMedGoogle Scholar
  33. 33.
    Eckardt A, Starke O, Stadler M et al (2004) Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 40(8):811–814PubMedCrossRefGoogle Scholar
  34. 34.
    Fricain JC, Sibaud V, Swetyenga N, Tabrizi R, Campana F, Taieb A (2007) Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. Br J Dermatol 156(3):588–590PubMedCrossRefGoogle Scholar
  35. 35.
    Albert MH, Becker B, Schuster FR et al (2007) Oral graft vs. host disease in children—treatment with topical tacrolimus ointment. Pediatr Transplant 11(3):306–311PubMedCrossRefGoogle Scholar
  36. 36.
    Sánchez AR, Sheridan PJ, Rogers RS (2004) Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 75(4):613–619PubMedCrossRefGoogle Scholar
  37. 37.
    Conrotto D, Carrozzo M, Ubertalli AV et al (2006) Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Transplantation 27;82(8):1113–1115, Erratum in: Transplantation. 2007. 83(1):76CrossRefGoogle Scholar
  38. 38.
    Schlaak M, Treudler R, Colsman A, Al-Ali H, Simon JC (2008) Oral graft-versus-host disease: successful therapy with extracorporeal photopheresis and topical tacrolimus. J Eur Acad Dermatol Venereol 22(1):112–113PubMedGoogle Scholar
  39. 39.
    Epstein JB, Reece DE (1994) Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 13(1):81–86PubMedGoogle Scholar
  40. 40.
    Epstein JB, Truelove EL (1996) Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82(5):532–536PubMedCrossRefGoogle Scholar
  41. 41.
    Deeg HJ, Socié G, Schoch G et al (1996) Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 87(1):386–392PubMedGoogle Scholar
  42. 42.
    Menillo SA, Goldberg SL, McKiernan P, Pecora AL (2001) Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation. Bone Marrow Transplant 28(8):807–808PubMedCrossRefGoogle Scholar
  43. 43.
    Redding SW, Callander NS, Haveman CW, Leonard DL (1998) Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86(2):183–187PubMedCrossRefGoogle Scholar
  44. 44.
    Atkinson K, Weller P, Ryman W, Biggs J (1986) PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1(2):227–236PubMedGoogle Scholar
  45. 45.
    Elad S, Garfunkel AA, Enk CD et al (1999) Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88(4):444–450PubMedCrossRefGoogle Scholar
  46. 46.
    Chor A et al (2004) Successful treatment of oral lesions of chronic lichenoid graft-vs.-host disease by the addition of low-level laser therapy to systemic immunosuppression. Eur J Haematol 72:222–224PubMedCrossRefGoogle Scholar
  47. 47.
    Greinix HT, Volc-Platzer B, Rabitsch W et al (1998) Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92(9):3098–3104PubMedGoogle Scholar
  48. 48.
    Mawardi H, Stevenson K, Gokani B et al (2009) Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant 45:1062–1067PubMedCrossRefGoogle Scholar
  49. 49.
    Epstein JB, Gorsky M, Epstein MS, Nantel S (2001) Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91(1):56–61PubMedCrossRefGoogle Scholar
  50. 50.
    Sullivan KM, Witherspoon RP, Storb R et al (1988) Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72(2):546–554PubMedGoogle Scholar
  51. 51.
    Curtis RE, Metayer C, Rizzo JD et al (2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105(10):3802–3811PubMedCrossRefGoogle Scholar
  52. 52.
    Yamashita S, Sato S, Kakiuchi Y et al (2002) Lidocaine toxicity during frequent viscous lidocaine use for painful tongue ulcer. J Pain Symptom Manage 24(5):543–545PubMedCrossRefGoogle Scholar
  53. 53.
    Elad S, Cohen G, Zylber-Katz E et al (1999) Systemic absorption of lidocaine after topical application for the treatment of oral mucositis in bone marrow transplantation patients. J Oral Pathol Med 28(4):170–172PubMedCrossRefGoogle Scholar
  54. 54.
    Nozaki-Taguchi N, Shutoh M, Shimoyama N (2008) Potential utility of peripherally applied loperamide in oral chronic graft-versus-host disease related pain. Jpn J Clin Oncol 38(12):857–860PubMedCrossRefGoogle Scholar
  55. 55.
    Elad S, Or R, Shapira MY et al (2003) CO2 laser in oral graft-versus-host disease: a pilot study. Bone Marrow Transplant 32(10):1031–1034PubMedCrossRefGoogle Scholar
  56. 56.
    Singhal S, Powles R, Treleaven J et al (1997) Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 24(5–6):539–543PubMedCrossRefGoogle Scholar
  57. 57.
    Nagler RM, Nagler A (2001) The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. Arch Oral Biol 46(8):689–695PubMedCrossRefGoogle Scholar
  58. 58.
    Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L et al (2007) Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 39:431–434PubMedCrossRefGoogle Scholar
  59. 59.
    Grisius MM (2001) Salivary gland dysfunction: a review of systemic therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:156–162PubMedCrossRefGoogle Scholar
  60. 60.
    Fife RS, Chase WF, Dore RK et al (2002) Cevimeline for the treatment of xerostomia in patients with Sjögren’s syndrome: a randomized trial. Arch Int Med 162:1293–1300CrossRefGoogle Scholar
  61. 61.
    Petrone D, Condemi JJ, Fife R et al (2002) A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46(3):748–754PubMedCrossRefGoogle Scholar
  62. 62.
    Yasuda H, Niki H (2002) Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjögren’s Syndrome. Clin Drug Invest 22(2):67–73CrossRefGoogle Scholar
  63. 63.
    Carpenter PA, Schubert MM, Flowers ME (2006) Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant 12(7):792–794PubMedCrossRefGoogle Scholar
  64. 64.
    Hahnel S, Behr M, Handel G, Bürgers R (2009) Saliva substitutes for the treatment of radiation-induced xerostomia-a review. Support Care Cancer J 17(11):1331–1343CrossRefGoogle Scholar
  65. 65.
    Majorana A, Schubert MM, Porta F et al (2000) Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management. Support Care Cancer 8(5):353–365PubMedCrossRefGoogle Scholar
  66. 66.
    Strietzel FP, Martín-Granizo R, Fedele S et al (2007) Electrostimulating device in the management of xerostomia. Oral Dis 13(2):206–213PubMedCrossRefGoogle Scholar
  67. 67.
    Pines M et al (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9(7):417–425PubMedCrossRefGoogle Scholar
  68. 68.
    Dahllöf G, Jönsson A, Ulmner M, Huggare J (2001) Orthodontic treatment in long-term survivors after pediatric bone marrow transplantation. Am J Orthod Dentofacial Orthop 120(5):459–465PubMedCrossRefGoogle Scholar
  69. 69.
    van der Pas-van Voskuilen IG, Veerkamp JS, Raber-Durlacher JE, Bresters D, van Wijk AJ, Barasch A, McNeal S, Gortzak RA (2009) Long-term adverse effects of hematopoietic stem cell transplantation on dental development in children. Support Care Cancer 17(9):1169–1175PubMedCrossRefGoogle Scholar
  70. 70.
    American Academy on Pediatric Dentistry Clinical Affairs Committee, American Academy on Pediatric Dentistry Council on Clinical Affairs (2008–2009) Guideline on dental management of pediatric patients receving chemotherapy, hematopoietic cell transplantation, and/or radiation. Pediatr Dent 30(7 Suppl):219–225Google Scholar
  71. 71.
    Brennan MT, Woo SB, Lockhart PB (2008) Dental treatment planning and management in the patient who has cancer. Dent Clin North Am 52(1):19–37PubMedCrossRefGoogle Scholar
  72. 72.
    Wilson W, Taubert KA, Gewitz M et al (2007) Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 138(6):739–745, 747–760PubMedGoogle Scholar
  73. 73.
    Little JW, Falace DA, Miller CS, Rhodus NL (2008) Dental management of the medically compromised patient, 7th edn. Mosby Elsevier, St. LouisGoogle Scholar
  74. 74.
    Ruggiero SL, Drew SJ (2007) Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86:1013–1021PubMedCrossRefGoogle Scholar
  75. 75.
    Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587PubMedCrossRefGoogle Scholar
  76. 76.
    Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102PubMedCrossRefGoogle Scholar
  77. 77.
    Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836PubMedCrossRefGoogle Scholar
  78. 78.
    Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303–1317PubMedCrossRefGoogle Scholar
  79. 79.
    Boonyapakorn T, Schirmer I, Reichart PA et al (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44(9):857–869PubMedCrossRefGoogle Scholar
  80. 80.
    Ruggiero SL, Dodson TB, Assael LA et al (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67:2–12PubMedGoogle Scholar
  81. 81.
    Groetz et al (2006) The guidelines of the German society of dentistry and oral medicine (DGZMK). Dtsch Zahnarztl Z 61:510–513Google Scholar
  82. 82.
    Scully C, Madrid C, Bagan J (2006) Dental endosseous implants in patients on bisphosphonate therapy. Implant Dent 15(3):212–218PubMedCrossRefGoogle Scholar
  83. 83.
    Montefusco V, Gay F, Spina F et al (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49(11):2156–2162PubMedCrossRefGoogle Scholar
  84. 84.
    Colella G, Campisi G, Fusco V et al (2009) American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws—2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67(12):2698–2699PubMedCrossRefGoogle Scholar
  85. 85.
    Leisenring W, Friedman DL, Flowers ME (2006) Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24(7):1119–1126PubMedCrossRefGoogle Scholar
  86. 86.
    Trullenque-Eriksson A, Muñoz-Corcuera M, Campo-Trapero J et al (2009) Analysis of new diagnostic methods in suspicious lesions of the oral mucosa. Med Oral Patol Oral Cir Bucal 14(5):E210–E216PubMedGoogle Scholar
  87. 87.
    Mehrotra R, Hullmann M, Smeets R et al (2009) Oral cytology revisited. J Oral Pathol Med 38(2):161–166PubMedCrossRefGoogle Scholar
  88. 88.
    Patton LL, Epstein JB, Kerr AR (2008) Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. J Am Dent Assoc 139(7):896–905PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Johannes K.-H. Meier
    • 1
  • Daniel Wolff
    • 2
  • Steve Pavletic
    • 3
  • Hildegard Greinix
    • 4
  • Martin Gosau
    • 1
  • Hartmut Bertz
    • 5
  • Stefanie J. Lee
    • 6
  • Ánita Lawitschka
    • 7
  • Sharon Elad
    • 8
  1. 1.Department of Cranio-Maxillo-Facial SurgeryUniversity of RegensburgRegensburgGermany
  2. 2.Department of Haematology and OncologyUniversity of RegensburgRegensburgGermany
  3. 3.Experimental Transplantation and Immunology Branch, Center of Cancer ResearchNational Cancer InstituteBethesdaUSA
  4. 4.Department of Internal Medicine IMedical University of ViennaViennaAustria
  5. 5.Department of Haematology and OncologyAlbert Ludwigs University Medical Centre FreiburgFreiburgGermany
  6. 6.Division of Clinical ResearchFred Hutchinson Cancer Research CenterSeattleUSA
  7. 7.Department of stem cell transplantationSt. Anna Children’s HospitalViennaAustria
  8. 8.Department of Oral MedicineThe Hebrew University—Hadassah School of Dental MedicineJerusalemIsrael

Personalised recommendations